PubMed Health⌕ Search

Biomedical subjects

Joyce L Murata-Collins

Publications and source records attributed to Joyce L Murata-Collins.

4 recordsLinked to original sources

Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases.

Acute myeloid leukemia (AML) occurring concurrently with or after untreated chronic lymphocytic leukemia (CLL) is rare. We report a case of a 59-year-old man who was evaluated for anemia, thrombocytopenia, and leukocytosis with circulating blasts. On the basis of the morphology and immunophenotyping results, a preliminary diagnosis of chronic myelomonocytic leukemia with concurrent CLL was considered. Subsequently, cytogenetic analysis of the leukemic blood specimen revealed inv(16)(p13.1q22) with secondary trisomy 22 in a sideline clone. Fluorescence in situ hybridization confirmed the CBFbeta rearrangement associated with inv(16) in myeloblasts and myelomonocytic cells, but not in CLL cells. Therefore, a final diagnosis of AML with inv(16) with concurrent CLL was made. After standard chemotherapy for AML, the patient achieved complete remission for both his AML and CLL. The unique aspects of this case include concomitant AML and CLL, which do not share clonality, complex cytogenetic abnormalities with trisomy 22 as a secondary abnormality associated with inv(16), and achievement of remission for both AML and CLL by AML chemotherapy regimen. This case also represents one of the rare instances where a diagnosis of AML can be established even when the blast percentage in the marrow and blood is less than 20%.

Blast Crisis↗

Ewing sarcoma as a second malignant neoplasm after acute lymphoblastic leukemia.

Second malignant neoplasms (SMNs) are being increasingly recognized. This report describes a case of a 7-year-old girl with a history of acute lymphoblastic leukemia (ALL) who presented with a mass in her humerus that was diagnosed as Ewing sarcoma. Second malignant neoplasms are relatively rare in survivors of ALL treated without radiation. Even more unusual is the development of Ewing sarcoma as the SMN.

Bone Neoplasms↗

Targeting multiple genetic aberrations in isolated tumor cells by spectral fluorescence in situ hybridization.

PURPOSE: Tumorigenesis is characterized by the stepwise accumulation of multiple genetic changes that modify specific growth controls and cell survival. Conventional fluorescence in situ hybridization (FISH) assays reliably target one to three probes in a single hybridization. Simultaneous detection of more than three chromosomal or gene targets should increase the overall power of molecular cytogenetics by permitting detection of multiple genetic aberrations at the single cell level. METHOD: Spectral FISH (S-FISH) is an innovative molecular cytogenetic approach that can target many specific chromosomal aberrations in interphase and metaphase cells in a single hybridization, using combinatorial fluorescence and digital imaging microscopy. RESULTS: S-FISH is a reliable means to identify disease-specific aberrations at the DNA level in individual tumor cells in hematopoietic disorders and malignant melanoma. CONCLUSION: S-FISH is a sensitive assay for the diagnosis and monitoring of disease-specific or patient-specific genetic aberrations, with significant clinical application in oncology for early detection of new or re-emerging abnormal clones, allowing for earlier therapeutic intervention.

Acute Disease↗